Back to Search Start Over

Incidence of allopurinolā€induced severe cutaneous adverse drug reaction in Malaysia

Authors :
Wei Leik Ng
Kheng Seang Lim
Vidhya Hariraj
Sing Chet Lee
Wee Kee Wo
Azuana Ramli
Pauline Siew Mei Lai
Si Lei Fong
Jing Ran Lim
Source :
British Journal of Clinical Pharmacology. 88:3782-3788
Publication Year :
2022
Publisher :
Wiley, 2022.

Abstract

Allopurinol is known to cause severe cutaneous adverse drug reactions (SCAR) in Malaysia. However, the incidence of allopurinol-induced SCAR is unknown. Therefore, we aimed to determine the incidence of allopurinol-induced SCAR in Malaysia over 5 years from 2015 to 2019.This retrospective analysis was done in collaboration with the National Pharmaceutical Regulatory Agency (NPRA). All allopurinol-induced adverse drug reaction cases reported to NPRA from 2015 to 2019 were extracted. Allopurinol-induced SCAR cases were identified and the incidence over the 5 years was calculated.Incidence of allopurinol-induced SCAR averaged at 2.5 cases per 1000 new users over the 5-year period, with a reducing trend from 3.2 per 1000 new users in 2015 to 2.25 per 1000 in 2019; despite the increasing number of adverse drug reaction cases being reported over the years. Stevens-Johnson syndrome was the commonest form of allopurinol-induced SCAR reported, at 143 cases (46.8% of total SCAR reported). Among Malaysia's 3 main ethnicities, the Chinese had the highest percentages of allopurinol-induced SCAR when compared to the Bumiputera and Indians (3.18 × 10The estimated incidence of allopurinol-induced SCAR in Malaysia from 2015 to 2019 was 2.5 cases per 1000 new users. This figure is consistent with the incidence reported in other Asian countries, namely Taiwan and Thailand.

Details

ISSN :
13652125 and 03065251
Volume :
88
Database :
OpenAIRE
Journal :
British Journal of Clinical Pharmacology
Accession number :
edsair.doi.dedup.....545b54db67858ed6a5c88587a5597e0a
Full Text :
https://doi.org/10.1111/bcp.15327